Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
Jun 12, 2026
•
4 min read
Takeda bodies Sotyktu in a head-to-head, Penumbra gets its stroke green light, and Stockholm keeps the EHA data spigot open.
Jun 11, 2026
5 min read
Hot CPI and an oil-fueled risk-off dragged biotech down with the tape — even a record IPO and a Phase 3 win couldn't keep the screen green.
Jun 10, 2026
GSK reaches for the checkbook, Parabilis breaks the IPO record, and AstraZeneca gatecrashes the GLP-1 party.
Jun 9, 2026
Incyte spends $2B dodging its own patent cliff, J&J buys into degraders sight-unseen, AZ's diet pill stays in the race — and biotech somehow still closes red.
Jun 8, 2026
Roche hands Nurix $700M for a BTK degrader, ADA can't stop shipping obesity data, and a chip rout drags the tape to its worst day since October.
Jun 5, 2026
3 min read
First CLDN18.2 ADC into a regulatory queue, Otsuka fights for its Voyxact read, and a new bill takes aim at the China licensing trade.
Jun 4, 2026
Biotech outpaced a softer tape as Alnylam struck a $2B AI pact, Lilly licensed Ascidian's RNA editing, and Iovance added Australia.
Jun 3, 2026
J&J's nipocalimab delivers in SLE, Travere strikes a $1B kidney licensing deal, and Novo exports oral Wegovy.
Jun 2, 2026
Roche lands Priority Review, Abivax’s UC readout gets a safety asterisk, and biotech lags a still-risk-on tape.
